

Physicians •
Hematology & Oncology

Thomas A. Alberico, MD
Burton F. Alexander, III, MD
Daniel M. Atienza, MD
Bruce W. Booth, MD
Robert L. Burger, MD, FACP
Paul R. Conkling, MD
Scott J. Cross, MD
Mark T. Fleming, MD
Edward R. George, MD, FACP
Elizabeth A. Harden, MD, FACP
John R. Howard, Jr., DO
John F. Kessler, MD, FACP
Scott Kruger, MD, FACP
Michael E. Lee, MD
John Q. A. Mattern, II, DO
Dean S. McCaughey, III, MD
John C. Paschold, MD, FACP
David M. Powell, MD
Christina W. Prillaman, MD, FACP
John J. Regan, MD
Ronald J. Ruszkowski, MD
S. George Saman, MD
Joseph J. Schulz, MD
Michael S. Steinberg, MD, FACP
Alexander K. Su, MD
Valiant D. Tan, MD

Gynecological Oncology

Johnny Hyde, MD
Munir F. Nasr, MD, FACP
Stacey J. Rogers, MD, FACP
Robert C. Squatrito, MD, FACP

Radiation Oncology

Michael L. Miller, DO

Office Locations
Southside

5900 Lake Wright Drive
Norfolk, VA 23502
(757) 466.8683
FAX (757) 466.8892

1950 Glenn Mitchell, Ste. 102
Virginia Beach, VA 23456
(757) 368.0437
FAX (757) 368.0492

5818 Harbour View Blvd, Suite 230
Suffolk, VA 23435
(757) 686.1042
TAX (757) 686.1055

102 Fairview Dr, Suite E
Franklin, VA 23851
(757) 569.9709
FAX (757) 569.6102

300 Medical Parkway, Suite 314
Chesapeake, VA 23320
(757) 549.4403
FAX (757) 549.4332

150 Burnett's Way, Suite 310
Suffolk, VA 23434
(757) 539.0670
FAX (757) 539.1062

Peninsula

895 Middle Ground Blvd, Bldg 200
Newport News, VA 23606
(757) 873.9400
FAX (757) 873.9420

3000 Coliseum Dr, Suite 104
Hampton, VA 23666
(757) 827.9400
FAX (757) 827.9320

3901 Trebyburn Dr, Suite 2A
Williamsburg, VA 23185
(757) 229.2236
FAX (757) 221.0409

6876 Main Street
Cloucester, VA 23061
(804) 693.3232
FAX (804) 693.3342

North Carolina

1513 B North Road St.
Elizabeth City, NC 27909
(252) 331.2044
FAX (252) 331.1909


5565 Croatan Highway
Kitty Hawk, NC 27949
(252) 261.5800
FAX (252) 261.5301

Central Business Office

5900 Lake Wright Dr, Suite 300
Norfolk, VA 23502
(757) 213.5700
FAX (757) 213.5701
TOLL FREE (800) 998.3450

Web Address

www.virginiacancer.com



NM582

USNRC Region I
Licensing Materials Section
475 Allendale Road
King of Prussia, PA 19406-1415

September 19, 2007

RE: NRC License Amendment Application

To Whom It May Concern:

Please accept this letter as a request to amend our Radioactive Materials License 45-25303-01, (Docket number 030-33574). We request to make a number of additions and deletions to our listing of authorized users.

Deletions from NRC 45-25303-01:

<u>Authorized User</u>	<u>Materials and Use</u>
David J. DiSantis, MD	35.100; 35.200
Andrew Ciric, MD	35.100; 35.200
Lamar Smith, MD	35.100; 35.200
Robert L. Chiavarini, MD	35.100; 35.200
Robert A. Woolfit, MD	35.100; 35.200
David L. Weaver, MD	35.100; 35.200
David M. Bridges, MD	35.100; 35.200
George H. Christian, MD	35.100; 35.200
Patsy J. Loiacono, MD	35.100; 35.200
William Glenn Horstman, MD	35.100; 35.200
Danlio Espinola, MD	35.100; 35.200

Additions to License NRC 45-25303-01:

<u>Authorized User</u>	<u>Materials and Use</u>
Man Hyong Kim, MD	35.100; 35.200
Robert Mariano, MD	35.100; 35.200
Jonathan C. White, MD	35.100; 35.200
Andrew P. Loiacono, MD	35.100; 35.200

Please note that all of the additions above are currently authorized under NRC License #45-11035-01, copy attached.

RECEIVED
REGION I
2007 OCT -1 PM 1:50

141136

NMSS/RGN1 MATERIALS-002

Should you have any questions regarding this application, please feel free to contact me.

Sincerely,

A handwritten signature in black ink, appearing to read 'E. George', written over a horizontal line.

Edward R. George, MD
Certifying Official
Virginia Oncology Associates, Inc.

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Sentara Virginia Beach General Hospital</p> <p>2. 1060 First Colonial Road Virginia Beach, Virginia 23454</p>	<p>In accordance with the letters dated April 16 and 18, 2007,</p> <p>3. License number 45-11035-01 is amended in its entirety to read as follows:</p> <p>4. Expiration date August 31, 2014</p> <p>5. Docket No. 030-03348 Reference No.</p>
---	---

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Palladium-103 permitted by 10 CFR 35.400</p> <p>E. Strontium 90</p> <p>F. Strontium 90</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed sources (Theragenics TheraSeed Model 200)</p> <p>E. Sealed sources (ARC Model B-1)</p> <p>F. Sealed sources (Radiochemical Centre Model SIC.7)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 500 millicuries</p> <p>D. 1,000 millicuries</p> <p>E. 20 millicuries</p> <p>F. 10 millicuries</p>
---	---	---

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
45-11035-01

Docket or Reference Number
030-03348

Amendment No. 45

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
- E. For storage incident to disposal of an ABC Model B-1 ophthalmic applicator.
- F. Calibration of the licensee's instruments.

CONDITIONS

- 10. A. Licensed material in Items 6.A. through 6.F. may be used or stored at the licensee's facilities located at 1060 First Colonial Road, Virginia Beach, Virginia.
- B. Licensed material in Item 6.B. may be used or stored at the licensee's facilities located at Tidewater Cardiovascular Institute (TCI), 1708 Old Donation Parkway, Virginia Beach, Virginia, and Advanced Imaging Center, 1080 First Colonial Road, Virginia Beach, Virginia.
- C. Licensed material in Item 6.C. may be used or stored at the licensee's facilities located at Princess Anne Health Campus, Suite 100, 1950 Glenn Mitchell Drive, Virginia Beach, Virginia.
- 11. The Radiation Safety Officer for this license is Sandy J. Wolff, CHP, DABR.
- 12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized users for medical use as indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
Harry Alexander Allan, M.D.	35.100; 35.200
Ricardo De la Torre, M.D.	35.100; 35.200; 35.300
Mark Cramer, M.D.	35.100; 35.200; 35.300, except oral administration of greater than 33 millicuries of sodium iodide I-131
John G. Kenerson, M.D.	35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
45-11035-01

Docket or Reference Number
030-03348

Amendment No. 45

<u>Authorized Users</u>	<u>Material and Use</u>
Man Hyong Kim, M.D.	35.100; 35.200
John D. O'Neil, M.D.	35.100; 35.200
Jeffrey A. Klein, M.D.	35.100; 35.200; 35.300, except oral administration of greater than 33 millicuries of sodium iodide I-131
Douglas Charles Brown, M.D.	35.100; 35.200
Alan Zabell, M.D.	35.300; 35.400
Mark E. Shaves, M.D.	35.300; 35.400
Robert Mariano, M.D.	35.100; 35.200
Demetrios James Kazakis, M.D.	35.100; 35.200
Jonathan C. White, M.D.	35.100; 35.200; 35.300
Deepak R. Tareja	35.200
Scott Seth Williams, M.D.	35.300; 35.400
Mark S. Sinesi, M.D.	35.300; 35.400
Andrew P. Loiacono, M.D.	35.100; 35.200; Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries

C. The following individuals are authorized users for non-medical uses as indicated:

<u>Users</u>	<u>Material and Use</u>
Sandy J. Wolff, CHP, DABR	Strontium 90 (ARC Model B-1) for supervision of storage; Strontium 90 (Radiochemical Centre Model SIC.7) for calibration of instruments

13. The intravascular brachytherapy afterloader device shall be inspected and serviced at intervals recommended by the manufacturer, and maintenance and repair shall be performed by the manufacturer or persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
45-11035-01Docket or Reference Number
030-03348

Amendment No. 45

14. The authorized medical physicist shall perform independent measurement of intravascular brachytherapy source output, before the first patient treatment, using a dosimetry system that meets the requirements of 10 CFR 35.630(a).
15. The licensee shall survey the patient and intravascular brachytherapy catheter immediately following source retraction or removal to confirm complete retraction of the source(s) as specified in 10 CFR 35.404.
16. For sealed sources not associated with 10 CFR Part 35 use, the following conditions apply:
- A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed six months or at the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State.
 - B. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.
 - C. Sealed sources need not be tested if they contain only hydrogen-3, or they contain only a radioactive gas; or the half-life of the isotope is 30 days or less; or they contain not more than 100 microcuries of beta- and/or gamma-emitting material or not more than 10 microcuries of alpha-emitting material.
 - D. Sealed sources need not be tested if they are in storage and are not being used; however, when they are removed from storage for use or transferred to another person and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.
 - E. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.
 - F. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or by other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.
 - G. Records of leak test results shall be kept in units of microcuries and shall be maintained for 5 years.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number


45-11035-01

Docket or Reference Number

030-03348

Amendment No. 45

17. The licensee shall conduct a physical inventory every six months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 5 years from the date of each inventory and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.
18. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.
19. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
20. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.




**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
45-11035-01Docket or Reference Number
030-03348

Amendment No. 45

21. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated February 19, 2004, excluding attachments 9.2-9.4 and Item 10 (ML040620116)
- B. Letter dated May 12, 2004 (ML041390243)
- C. Letter dated June 25, 2004 (ML041950373)
- D. Letter dated January 4, 2006 (ML060230101)
- E. Letter dated May 24, 2006 (ML061660533)
- F. Letter dated October 6, 2006 (ML063110365)
- G. Letter dated January 11, 2007 (ML070120428)



For the U.S. Nuclear Regulatory Commission

Date May 31, 2007

By

Original signed by Shirley Xu

Shirley Xu
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406

Thursday, May 31, 2007 10:34:40 AM

This is to acknowledge the receipt of your letter/application dated

9/19/2007, and to inform you that the initial processing which includes an administrative review has been performed.

AMEND. 45-25303-01
There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 141135.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.